Cabio Biotech Wuhan Co Ltd (688089) - Total Liabilities
Based on the latest financial reports, Cabio Biotech Wuhan Co Ltd (688089) has total liabilities worth CN¥183.42 Million CNY (≈ $26.84 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check asset resilience ratio of Cabio Biotech Wuhan Co Ltd to evaluate the company's liquid asset resilience ratio.
Cabio Biotech Wuhan Co Ltd - Total Liabilities Trend (2013–2024)
This chart illustrates how Cabio Biotech Wuhan Co Ltd's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see balance sheet size of Cabio Biotech Wuhan Co Ltd.
Cabio Biotech Wuhan Co Ltd Competitors by Total Liabilities
The table below lists competitors of Cabio Biotech Wuhan Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
ZongTai Real Estate Development Co Ltd
TW:3056
|
Taiwan | NT$6.78 Billion |
|
ASIX Electronics
TWO:3169
|
Taiwan | NT$418.38 Million |
|
KABE Group AB (publ.)
ST:KABE-B
|
Sweden | Skr1.00 Billion |
|
Central Omega Resources Tbk PT
JK:DKFT
|
Indonesia | Rp1.84 Trillion |
|
Ohio Valley Banc Corp
NASDAQ:OVBC
|
USA | $1.51 Billion |
|
OraSure Technologies Inc
NASDAQ:OSUR
|
USA | $62.34 Million |
|
Thayer Ventures Acquisition Corporation II Class A Ordinary Shares
NASDAQ:TVAI
|
USA | $9.23 Million |
|
Clarke Inc.
TO:CKI
|
Canada | CA$376.42 Million |
Liability Composition Analysis (2013–2024)
This chart breaks down Cabio Biotech Wuhan Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See 688089 equity to assets ratio to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.79 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.11 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.10 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Cabio Biotech Wuhan Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Cabio Biotech Wuhan Co Ltd (2013–2024)
The table below shows the annual total liabilities of Cabio Biotech Wuhan Co Ltd from 2013 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥117.27 Million ≈ $17.16 Million |
-0.28% |
| 2023-12-31 | CN¥117.60 Million ≈ $17.21 Million |
-36.69% |
| 2022-12-31 | CN¥185.77 Million ≈ $27.18 Million |
+178.61% |
| 2021-12-31 | CN¥66.68 Million ≈ $9.76 Million |
+12.44% |
| 2020-12-31 | CN¥59.30 Million ≈ $8.68 Million |
+22.89% |
| 2019-12-31 | CN¥48.26 Million ≈ $7.06 Million |
-12.25% |
| 2018-12-31 | CN¥54.99 Million ≈ $8.05 Million |
+31.01% |
| 2017-12-31 | CN¥41.98 Million ≈ $6.14 Million |
-43.41% |
| 2016-12-31 | CN¥74.17 Million ≈ $10.85 Million |
-13.35% |
| 2015-12-31 | CN¥85.60 Million ≈ $12.53 Million |
+106.19% |
| 2014-12-31 | CN¥41.52 Million ≈ $6.08 Million |
+4.62% |
| 2013-12-31 | CN¥39.68 Million ≈ $5.81 Million |
-- |
About Cabio Biotech Wuhan Co Ltd
Cabio Biotech (Wuhan) Co., Ltd. develops, produces, and markets arachidonic and docosahexaenoic acids, and beta-carotene for domestic and foreign infant formula, and healthy food manufacturers. It offers human and animal nutrition, personal care, and synthetic biology products. The company was founded in 1999 and is based in Wuhan, the People's Republic of China.